Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer

Hsian Yu Wang, Yu Ling Chang, Chun Chun Cheng, Min Wu Chao, Su I. Lin, Shiow-Lin Pan, Chih Cheng Hsu, Tsang Wu Liu, Han Chin Cheng, Ching Ping Tseng, Shih Jen Liu, Hui Ju Tsai, Hsing Yi Chang, John T A Hsu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitors (TKIs) have shown remarkable benefits in non-small cell lung cancer (NSCLC) patients with drug-sensitive mutations in the EGFR gene. Responsive patients are usually continuously prescribed with TKIs until disease progression. Glucocorticoids (GCs) are potent homeostasis maintaining drugs and are frequently used in cancer patients to alleviate discomforts caused by anti-cancer therapies. Several previous studies reported that concomitant use of GCs may compromise the efficacy of chemo-therapeutics in patients with solid tumors. Little is known in the concomitant use of target therapy with GCs in treating NSCLC. In this study, we hypothesized that concomitant use of GCs in EGFR-TKI therapy may be detrimental and addressed this issue using cell cultures and xenograft studies followed by a retrospective population study based on data from the Taiwan national health insurance system. In cell cultures and xenograft studies, GCs were shown to unequally compromise the anti-cancer efficacy of TKIs in both PC9 and NCI-H1975 NSCLC cells models. In the retrospective population study, patients with similar disease status that were co-medicated with GCs had a significantly higher risk of disease progression.

Original languageEnglish
Pages (from-to)85917-85928
Number of pages12
JournalOncotarget
Volume7
Issue number52
Publication statusPublished - 2016

Fingerprint

Non-Small Cell Lung Carcinoma
Glucocorticoids
Protein-Tyrosine Kinases
Epidermal Growth Factor Receptor
Heterografts
Disease Progression
Neoplasms
Retrospective Studies
Cell Culture Techniques
erbB-1 Genes
National Health Programs
Therapeutics
Taiwan
Pharmaceutical Preparations
Population
gefitinib
Homeostasis
Mutation

Keywords

  • EGFR
  • Glucocorticoids
  • National health insurance research database taiwan
  • NSCLC
  • TKI

ASJC Scopus subject areas

  • Oncology

Cite this

Wang, H. Y., Chang, Y. L., Cheng, C. C., Chao, M. W., Lin, S. I., Pan, S-L., ... Hsu, J. T. A. (2016). Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer. Oncotarget, 7(52), 85917-85928.

Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer. / Wang, Hsian Yu; Chang, Yu Ling; Cheng, Chun Chun; Chao, Min Wu; Lin, Su I.; Pan, Shiow-Lin; Hsu, Chih Cheng; Liu, Tsang Wu; Cheng, Han Chin; Tseng, Ching Ping; Liu, Shih Jen; Tsai, Hui Ju; Chang, Hsing Yi; Hsu, John T A.

In: Oncotarget, Vol. 7, No. 52, 2016, p. 85917-85928.

Research output: Contribution to journalArticle

Wang, HY, Chang, YL, Cheng, CC, Chao, MW, Lin, SI, Pan, S-L, Hsu, CC, Liu, TW, Cheng, HC, Tseng, CP, Liu, SJ, Tsai, HJ, Chang, HY & Hsu, JTA 2016, 'Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer', Oncotarget, vol. 7, no. 52, pp. 85917-85928.
Wang HY, Chang YL, Cheng CC, Chao MW, Lin SI, Pan S-L et al. Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer. Oncotarget. 2016;7(52):85917-85928.
Wang, Hsian Yu ; Chang, Yu Ling ; Cheng, Chun Chun ; Chao, Min Wu ; Lin, Su I. ; Pan, Shiow-Lin ; Hsu, Chih Cheng ; Liu, Tsang Wu ; Cheng, Han Chin ; Tseng, Ching Ping ; Liu, Shih Jen ; Tsai, Hui Ju ; Chang, Hsing Yi ; Hsu, John T A. / Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer. In: Oncotarget. 2016 ; Vol. 7, No. 52. pp. 85917-85928.
@article{93481d978e0044648ced4758a1f2ca24,
title = "Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer",
abstract = "The epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitors (TKIs) have shown remarkable benefits in non-small cell lung cancer (NSCLC) patients with drug-sensitive mutations in the EGFR gene. Responsive patients are usually continuously prescribed with TKIs until disease progression. Glucocorticoids (GCs) are potent homeostasis maintaining drugs and are frequently used in cancer patients to alleviate discomforts caused by anti-cancer therapies. Several previous studies reported that concomitant use of GCs may compromise the efficacy of chemo-therapeutics in patients with solid tumors. Little is known in the concomitant use of target therapy with GCs in treating NSCLC. In this study, we hypothesized that concomitant use of GCs in EGFR-TKI therapy may be detrimental and addressed this issue using cell cultures and xenograft studies followed by a retrospective population study based on data from the Taiwan national health insurance system. In cell cultures and xenograft studies, GCs were shown to unequally compromise the anti-cancer efficacy of TKIs in both PC9 and NCI-H1975 NSCLC cells models. In the retrospective population study, patients with similar disease status that were co-medicated with GCs had a significantly higher risk of disease progression.",
keywords = "EGFR, Glucocorticoids, National health insurance research database taiwan, NSCLC, TKI",
author = "Wang, {Hsian Yu} and Chang, {Yu Ling} and Cheng, {Chun Chun} and Chao, {Min Wu} and Lin, {Su I.} and Shiow-Lin Pan and Hsu, {Chih Cheng} and Liu, {Tsang Wu} and Cheng, {Han Chin} and Tseng, {Ching Ping} and Liu, {Shih Jen} and Tsai, {Hui Ju} and Chang, {Hsing Yi} and Hsu, {John T A}",
year = "2016",
language = "English",
volume = "7",
pages = "85917--85928",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "52",

}

TY - JOUR

T1 - Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer

AU - Wang, Hsian Yu

AU - Chang, Yu Ling

AU - Cheng, Chun Chun

AU - Chao, Min Wu

AU - Lin, Su I.

AU - Pan, Shiow-Lin

AU - Hsu, Chih Cheng

AU - Liu, Tsang Wu

AU - Cheng, Han Chin

AU - Tseng, Ching Ping

AU - Liu, Shih Jen

AU - Tsai, Hui Ju

AU - Chang, Hsing Yi

AU - Hsu, John T A

PY - 2016

Y1 - 2016

N2 - The epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitors (TKIs) have shown remarkable benefits in non-small cell lung cancer (NSCLC) patients with drug-sensitive mutations in the EGFR gene. Responsive patients are usually continuously prescribed with TKIs until disease progression. Glucocorticoids (GCs) are potent homeostasis maintaining drugs and are frequently used in cancer patients to alleviate discomforts caused by anti-cancer therapies. Several previous studies reported that concomitant use of GCs may compromise the efficacy of chemo-therapeutics in patients with solid tumors. Little is known in the concomitant use of target therapy with GCs in treating NSCLC. In this study, we hypothesized that concomitant use of GCs in EGFR-TKI therapy may be detrimental and addressed this issue using cell cultures and xenograft studies followed by a retrospective population study based on data from the Taiwan national health insurance system. In cell cultures and xenograft studies, GCs were shown to unequally compromise the anti-cancer efficacy of TKIs in both PC9 and NCI-H1975 NSCLC cells models. In the retrospective population study, patients with similar disease status that were co-medicated with GCs had a significantly higher risk of disease progression.

AB - The epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitors (TKIs) have shown remarkable benefits in non-small cell lung cancer (NSCLC) patients with drug-sensitive mutations in the EGFR gene. Responsive patients are usually continuously prescribed with TKIs until disease progression. Glucocorticoids (GCs) are potent homeostasis maintaining drugs and are frequently used in cancer patients to alleviate discomforts caused by anti-cancer therapies. Several previous studies reported that concomitant use of GCs may compromise the efficacy of chemo-therapeutics in patients with solid tumors. Little is known in the concomitant use of target therapy with GCs in treating NSCLC. In this study, we hypothesized that concomitant use of GCs in EGFR-TKI therapy may be detrimental and addressed this issue using cell cultures and xenograft studies followed by a retrospective population study based on data from the Taiwan national health insurance system. In cell cultures and xenograft studies, GCs were shown to unequally compromise the anti-cancer efficacy of TKIs in both PC9 and NCI-H1975 NSCLC cells models. In the retrospective population study, patients with similar disease status that were co-medicated with GCs had a significantly higher risk of disease progression.

KW - EGFR

KW - Glucocorticoids

KW - National health insurance research database taiwan

KW - NSCLC

KW - TKI

UR - http://www.scopus.com/inward/record.url?scp=85007492453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007492453&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 85917

EP - 85928

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 52

ER -